Abstract: Studies comparing rabbit monoclonal SP1 antibody with 1D5 for estrogen receptor (ER) immunohistochemical testing show conflicting results. Here we use a standardized quantitative immunofluorescent (QIF) ER assay to determine the level and significance of discordance between the antibodies. Both antibodies were assessed by QIF on our Index TMA of cell lines and case controls, followed by QIF and immunohistochemical analysis on 2 retrospective cohorts from Yale. On the Index TMA, SP1 displayed stronger signal-to-noise ratio compared with 1D5. On the patient cohorts, the range of discrepancy between the 2 antibodies was 8% to 16.9%, with the majority of discrepant cases being SP1 positive/1D5 negative. Kaplan-Meier analysis of the discrepant cases showed outcomes comparable to those of double-positive cases, suggesting that SP1 is more sensitive than 1D5. A series of cases with high levels of ER-b shows that neither antibody cross-reacts, suggesting equivalent specificity. Future efforts are needed to determine whether response to endocrine therapies show superiority of either antibody as a companion diagnostic test.
T he estrogen receptor (ER) is arguably the most successful biomarker that exists in breast cancer today, determining both patient prognosis and eligibility for endocrine therapies. 1, 2 Because endocrine therapy provides a significant survival benefit, but only in ER-positive patients, [3] [4] [5] accurate ER testing is critical. Although it has been shown to be equivalent or superior to the previous ligand-binding assay (LBA), 6, 7 it is widely acknowledged that measurement of ER by the current standard, immunohistochemistry (IHC), still has many flaws, including the subjectivity involved in measurement and interpretation, [8] [9] [10] as well as variability due to preanalytic factors, some of which are still not understood. 8, 11 Much of this variability stems from how rapidly IHC methods replaced those of LBA and ELISA in the clinical setting. The advantages of IHC (low cost, ease of analysis, and applicability on routine samples and small tumors) were so obvious that as soon as correlative studies between IHC and LBA were performed, most laboratories converted to IHC before standardized protocols, reagents, and thresholds were determined. 12 A single incident in Canada, which involved retesting ER status in 1000 cases from 1997 to 2005, finding 40% misclassification between local and central laboratories, 13 sparked widespread awareness and concerns regarding false-negative ER classification. Our previous studies, as well as those done by other larger multinational cooperative groups, have estimated a 10% to 20% false-negative rate in current US clinical practice, suggesting significant potential undertreatment. [14] [15] [16] [17] [18] [19] New guidelines have recently been issued by the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP), which aim to address the falsenegative problem by lowering the threshold for ER positivity from 10% of nuclei "positive" to 1%. 20 However, evidence from our recent work has suggested that false-negative ER classification is caused primarily by variability in the threshold of intensity (what constitutes a "positive" nucleus), regardless of what percentage of them are positive. 17 We have recently described a quantitative immunofluorescence-based (QIF) assay for ER, to help standardize how the threshold for ER positivity is determined. 17 This assay uses a control tissue microarray (called the Index TMA) that contains a number of cell lines as well as a panel of 40 cases spanning the range of ER expression, which is stained alongside every experimental cohort to reproducibly determine the threshold for ER positivity. Here we examine how the use of different antibodies affects this threshold.
Three ER antibodies are currently clinically validated and approved by ASCO/CAP for ER testing (1D5, SP1, and 6F11). 5, 6, 14, [20] [21] [22] Studies have suggested that compared with 1D5, SP1 has an 8Â greater affinity for ER by ELISA, and is more sensitive (but still as specific) on formalin-fixed, paraffin-embedded (FFPE) tissue. 23, 24 The existing data comparing the antibodies on large patient cohorts are minimal, but conflicting. One large study performed on over 4000 cases of frozen tissue on TMAs suggested that SP1 is more sensitive than 1D5 (using biochemical assays as the gold standard), that 8% of cases were SP1 positive but 1D5 negative, and that these cases were associated with better outcomes. 22 A later prospectively designed study was performed on consecutive cases analyzed for routine clinical testing (fresh whole sections that were FFPE), and found only 2 of 508 carcinoma cases to be discrepant when comparing the 2 antibodies. 25 Given our ability to objectively assess the threshold for ER positivity using the Index TMA, we first sought to determine if SP1 and 1D5 showed similar sensitivity using QIF on this panel of cell line and patient controls. We then examined 2 retrospective cohorts from Yale (YTMA 49 and YMA 128) using both antibodies, and compared the level and significance of their discordance in determining ER status, both by traditional IHC and our novel QIF assay.
MATERIALS AND METHODS

Cell Line Panel and Culture
A panel of ATCC breast cancer cell lines (Fig. 1B) was chosen to span a range of ER expression. All cells were maintained at 371C and 5% CO 2 , and grown either in suggested media, or in RPMI 1640 culture medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Gemini BioProducts), 100 U/mL penicillin G and 100 mg/mL streptomycin (Gibco), 1 mM sodium pyruvate (Gibco), and 2 mM L-glutamine (Gibco).
Western Blotting
Whole cell lysates were prepared in buffer containing 1% Nonidet P-40, 20 nM TrisHCl pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM DTT, 1 mM NaVO 3 , and complete mini EDTA-free protease inhibitor cocktail (Roche) in dH 2 O. Each lysate (15 mg) was resolved by SDS-PAGE on a 4% to 12% Bis-Tris gel (NuPage), using NuPage MOPS SDS Running Buffer at 45 mA. Resolved protein was transferred using NuPage Transfer Buffer at 50 V for 2 h. Western blotting was performed according to standard procedures, using ER using rabbit monoclonal SP1 antibody (Thermo), diluted 1:500. b-tubulin (Cell Signaling Technology, 2146), diluted 1:4000, was used as a loading control.
Construction of the Index TMA
Whole cell pellets (FFPE) were created from each of the cell lines in the panel (for a detailed protocol, see Dolled-Filhart et al 26 
Immunofluorescent (IF) Staining and AQUA Analysis
IF staining for ER was performed on the Index TMA and on sequential cuts of both YTMA 49 and YTMA 128. Slides were deparaffinized by melting at 601C for 20 minutes, followed by soaking twice for 20 minutes in xylene (JT Baker). Rehydration was performed twice in 100% EtOH for 1 minute, followed by 70% EtOH for 1 minute, and tap water for 5 minutes. Antigen retrieval was performed in citrate buffer (3.84 g sodium citrate dihydrate in 2 L ddH 2 O, brought to pH 6.0 with 1 M citric acid) using the PT module from LabVision. Endogenous peroxidases were blocked by 30-minute incubation in 2.5% hydrogen peroxide in methanol at room temperature (RT). After washing, nonspecific antigens were blocked by incubation in 0.3% bovine serum albumin in TBST for 30 minutes at RT in humidity chamber. Rabbit Cytokeratin (Dako), diluted 1:100 in block (BSA in TBST above), and was incubated overnight at 41C. ER was stained using 1D5 antibody (Dako, 1:50 in block, incubated 1 h at RT), or SP1 antibody (Thermo, 1:1000 in block, incubated overnight at 41C). ER-b expression was assessed using PPG5/10 (Thermo-Scientific) for ERb1 and Clone 5/25 (Serotec) for ERb5. Primary antibodies were followed by Alexa 546-conjugated goat anti-rabbit or anti-mouse secondary antibody (Molecular Probes) diluted 1:100 in mouse or rabbit EnVision reagent (Dako) for 1 hour at RT. Signal was amplified using Cyanine 5 (Cy5)-tyramide (Perkin-Elmer) at a dilution of 1:50 for 10 minutes at RT. Nuclei were stained using 10 mg/mL DAPI (Molecular Probes) in block for 20 minutes at RT, and coverslips mounted with Prolong mounting medium (ProLong Gold, Molecular Probes).
ER IF was quantified using AQUA. Briefly, a series of high-resolution monochromatic images were captured by the PM-2000 microscope (HistoRx) using AQUAsition 2.2 software (HistoRx). Images were collected for each histospot after autofocus and autoexposure. Fluorophores included DAPI (to create nuclear compartment), Cy3 (Alexa 546-cytokeratin to distinguish tumor from stroma and create cytoplasmic compartment), and Cy5 for the target (ER). Image analysis was performed using AQUAnalysis 2.2 software (HistoRx), which binarizes the cytokeratin stain (each pixel being "on" or "off") to create an epithelial tumor "mask." It uses a clustering algorithm to assign each pixel, with 95% confidence, to either a nuclear or cytoplasmic compartment. The AQUA score of ER in each subcellular compartment (nuclear, cytoplasmic, and whole tumor mask) is calculated by dividing the ER pixel intensities by the area of the compartment within which they were measured. AQUA scores are normalized to the exposure time, bit depth, and lamp hours at which the images were captured, allowing scores collected at different exposure times to be directly comparable. For the purpose of this study, only nuclear AQUA scores were used in the analyses. The Index TMA contains both positive and negative controls, and is used to determine the threshold AQUA score for ER positivity with each antibody (see Welsh et al 17 for more information on this standardization method).
IHC Staining
IHC staining was performed on sequential cuts of YTMA 49 in a CLIA-certified laboratory, using either the 1D5 (Dako) or SP1 (Ventana) staining system for ER. Stained slides were digitally scanned using BioImagene and visually assessed using ImageViewer software (BioImagene). Each slide was scored by 3 blinded individuals (2 board-certified pathologists, D.L.R. and M.H.), for . ER status of cell lines was confirmed by Western blot analysis of lysates prepared from the same cultures used to construct the Index TMA (B). ER was also quantified in the patients on the Index TMA using SP1 [AQUA score distribution in (D)] and 1D5 [AQUA score distribution in (F)], revealing strong correlation between both antibodies (E, Pearson r 2 = 0.853, Spearman r rank = 0.975). On these 39 cases there was no discordance in ER status between the 2 antibodies, however the difference between the highest negative case and lowest positive case is much greater with SP1 [arrows and inset (D)] than with 1D5 [arrows and inset (F)]. QIF images of ER staining in these cases (designated with arrows) are shown in (G) along with their AQUA scores, with SP1 in the left panels and 1D5 in the right panels. In these images, we expanded the dynamic range of the grayscale around the threshold (adjusted maximum RGB input level from 255 to 17 using Adobe Photoshop) to visualize very low levels of specific nuclear staining as well as nonspecific background.
both intensity (0 to 3) and % positivity (0 to 100). Scores for each case were then binarized, using the new 1% threshold, 20 to be classified as either ER positive or negative.
Statistical Analysis
All statistical analyses (bivariate regressions, Spearman r correlations, univariate and multivariate analyses, and Kaplan-Meier survival analyses) were performed using StatView analysis software. Disease-specific survival was used as an endpoint.
RESULTS
SP1
Antibody Shows Higher Signal-to-Noise Ratio Than 1D5 on Index TMA To determine whether rabbit monoclonal antibody SP1 and mouse monoclonal 1D5 showed the same sensitivity by IF staining, we compared both antibodies on a panel of cell line and patient controls specifically designed for measurement of ER. We call this array the Index TMA, and it contains a panel of cell lines with known ER status that were cultured under normal conditions, then pelleted, FFPE, and cored as if a tissue block, for placement in duplicate on the TMA (see the Materials and methods section). The TMA was stained using IF with both antibodies, and nuclear immunoreactivity was quantified using AQUA software, which determines ER expression on a continuous scale represented as an AQUA score. IF measurement of ER in the cell line panel using SP1 produced AQUA scores with a range of 63 to 1432, with a 142-unit jump in score between the last negative cell line (MB 468, AQUA score 89) and the first positive cell line (ZR 751, AQUA score 231) (Fig. 1A) . Western blot analysis of ER using SP1 on lysates from the same cell lines (prepared in parallel with the FFPE cores) confirmed the expected ER positivity of the 4 cell lines with highest AQUA scores by IF (Fig. 1B) . However, IF measurement of ER in the cell line panel using 1D5 revealed AQUA scores with a smaller range than SP1 (145 to 871), with roughly a 90-unit jump in score between the last negative cell line (MDA-MB-231 in this case, AQUA score 284) and the first positive one (ZR 751, AQUA score 376) (Fig. 1C) . There was an overall higher level of background (nuclear immunoreactivity in ER negative cell lines) with 1D5 (scores ranging from 145 to 284) than SP1 (scores ranging from 63 to 89).
Both antibodies were also used to measure ER by IF on the panel of 40 control cases, which were also part of the Index TMA, and were chosen to span the full range of ER expression seen in patients. In this panel, SP1 showed a range of AQUA scores from 45 to 12,417 (Fig. 1D ), which were well correlated (Pearson r 2 = 0.85, Spearman r rank correlation = 0.975, Fig. 1E ), with the scores using 1D5, ranging from 107 to 10,635 (Fig. 1F) . In these 40 patient controls, the same cases were considered ER positive or negative with SP1 and 1D5, however, the difference between the last negative case and the first positive case was more than 3 times as robust with SP1 (250-unit jump in score from 74 to 323, see arrows and inset in Fig. 1D ) as compared with 1D5 (70-unit jump in score from 198 to 268, see arrows and inset in Fig. 1F ). When visually validating the ER status of these cases right at the threshold for ER positivity, this difference is clearly visible by eye with SP1 (Fig. 1G, left panel) , but much more difficult to distinguish specific nuclear immunoreactivity against nonspecific background with 1D5 (Fig. 1G, right panel) .
Comparison of SP1 With 1D5 on YTMA 49 Using Traditional IHC
To assess the clinical relevance of this observed difference in sensitivity, we next compared both antibodies using traditional IHC staining on a retrospective cohort of breast cancer cases from Yale (YTMA 49, clinicopathologic characteristics shown in Table 1 ). Two sequential 5 mm cuts of the TMA were stained in a CLIA-certified lab, using either the SP1 (Ventana) or 1D5 (Dako) system. The TMAs were then digitally scanned, and both independently scored by 3 blinded individuals (including 2 board-certified pathologists) for both intensity (0 to 3) and % positive nuclei (0 to 100). Cases were then binarized as either ER positive or negative according to the current ASCO-CAP guidelines, which define a 1% threshold for positivity. Comparison of ER status using both antibodies revealed 83.3% agreement (20.9% double negative, 62.4% double positive), but 16.7% disagreement, with the majority (65 of 73 total discrepant cases) ER positive by SP1, but negative by 1D5 (Fig. 2A) . To determine if the discrepancy was because of a difference in sensitivity of the antibodies, we examined the individual scores for intensity and % positivity in these cases. The scores for %-positive nuclei showed even distribution across the spectrum from 0 to 100 (Fig. 2B, top panels) . In contrast, the distribution of intensity scores were significantly skewed to the low end of the spectrum (Fig. 2B, bottom panels) , showing that the majority of discrepant cases had low levels of ER (given an intensity score of 1) that were detected with SP1, but missed with 1D5 (instead given an intensity score of 0).
Kaplan-Meier analysis revealed that the discrepant cases (SP1 positive/1D5 negative) showed disease-specific survival similar to "true" ER positives (positive with both antibodies), and trending towards significantly different than "true" ER negatives (log-rank P = 0.101, Fig. 2C ). Representative examples of discrepant cases are shown in Figure 2D (1D5 positive/SP1 negative in left panels, SP1 positive/1D5 negative in right panels).
Comparison of SP1 With 1D5 on YTMA 49 and YTMA 128 Using IF To confirm these findings using a second method, we also compared both antibodies in assessment of ER status using quantitative IF. Both antibodies were stained on 2 retrospective cohorts from Yale (YTMA 49 and YTMA 128) alongside the Index TMA, to standardize the AQUA score threshold for positivity using each antibody (see Welsh et al 17 for more information on standardization). Analysis of ER status for each case on YTMA 49 using both antibodies revealed 91.2% agreement and 8.8% discrepant cases, the majority of which were SP1 positive/1D5 negative (Fig. 3A) . Kaplan-Meier analysis revealed that these discrepant cases showed disease-specific survival similar to "true" ER positives (positive with both antibodies), and trending toward significantly different than "true" ER negatives (log-rank P = 0.159, Fig. 3B ). On this cohort, both antibodies are significant prognostic factors in a univariate Cox proportional hazards model; however, SP1 is stronger (P = 0.0027, hazard ratio = 1.965; compared with P = 0.01, hazard ratio = 1.72 with 1D5) (Table 2 ). Both antibodies also hold up on a multivariate Cox model, adjusted for age, nodal status, tumor size, and nuclear grade (Table 3) .
To confirm this level of discrepancy on a more recent cohort, we performed the same analysis on YTMA 128. Comparison of both antibodies on YTMA 128 revealed 11% discrepancy, this time with all discrepant cases positive by SP1, but negative by 1D5 (Fig. 3C) . This cohort is too recent to have sufficient follow-up, and thus Kaplan-Meier and Cox univariate analysis of diseasespecific survival were not performed. Representative IF images for discrepant cases, as well as cases in agreement, are shown in Figure 4 for each antibody, demonstrating that the difference in signal-to-noise ratio with both antibodies is visible by eye.
Finally, given the data above on sensitivity, we assessed antibody cross-reactivity to determine if there is a difference in antibody specificity. Since ER-b is the most closely related isoform, we measured ERb1 and ERb5 using validated antibodies PPG5/10 and Clone 5/25, respectively on YTMA-49. If there was cross-reactivity between SP1 or 1D5 and ER-b, then all cases positive for either ER-b antibody should also be positive for SP1 or 1D5. For each ER-b antibody, there were over 50 cases that were strongly positive for ER-b but completely negative for both SP1 and 1D5. Thus there seems to be no difference in specificity, at least with respect to ER-b.
DISCUSSION
In a panel of cell line and patient controls, we show that SP1 displays a stronger signal-to-background ratio than 1D5. On 2 retrospective cohorts, by IHC and IF, we see discrepancy between the 2 antibodies ranging from 8% to 16.9%, with the majority of (or in 1 cohort, all) discrepant cases positive by SP1, but negative by 1D5. Survival analysis of these cases shows that they are correlated with better outcomes than "true" ER-negative patients, suggesting that SP1 may be at least 8% more sensitive than 1D5. Furthermore, univariate Cox models suggest that while both antibodies are significant predictors of disease-specific survival, SP1 is slightly stronger. These results agree with Cheang et al, 22 who found that there is an 8% discrepancy between the 2 antibodies, and these discrepant cases (again SP1 positive/1D5 negative) correlate with better outcome and better response to Tamoxifen. Unfortunately, on our cohorts we could only examine disease-specific survival as a surrogate for ER "positivity" (as opposed to response to Tamoxifen), since 1 cohort pre-dated the routine use of Tamoxifen (YTMA 49), and the other was too recent to have followup information. We have also observed a higher level of discrepancy with IHC than QIF, which could be because of the added variability associated with the subjectivity of scoring IHC and variability of the chromogen. Regardless, the 8% (at least) level of discrepancy we have observed is contrary to the study by Brock et al, 25 There are a number of possible reasons for the level of discrepancy we have observed. Most obviously, 1D5 is a mouse, and SP1 a rabbit, monoclonal. A number of published studies suggest that rabbit monoclonals may display greater affinity for their epitope, 23, 24 and that SP1 itself is more sensitive than 1D5 on patient tissue. 22, 28 Although the epitopes themselves are different (SP1 is Cterminal, 1D5 is N-terminal), there is no known evidence to date of a prevalence of C-terminal ER isoforms in breast carcinoma cases. It has also been suggested that the 2 antibodies have different sensitivities to preanalytic variables, specifically that delays in fixation can affect loss of antigenicity for 1D5 more than for SP1. 29 Finally it is possible that there may be a difference because of structurally defective ER. 30 Another key issue, which was raised in the study by Brock et al, 25 is the use of TMAs, given their limitations with regard to heterogeneity. The use of TMAs was deliberate in this study since we were interested in comparing sensitivity of both antibodies at the threshold for positivity, and to minimize variability in threshold, wanted to compare all cases on a single slide. However, we recognize that this is a limitation of this work. Previous data have suggested that 2 tissue cores on a TMA is enough to achieve >95% reproducibility, 31 whereas more recent studies suggest that a large number of "fields of view" are required to address issues of heterogeneity. Here, we only tested a single core from each patient. If we assume SP1 to be more sensitive than 1D5, as our data suggest, this problem of heterogeneity and representation would explain the small proportion of 1D5-positive/SP1-negative cases we have observed (perhaps these are true ER-positive cases, and on a whole tissue section, would be positive with SP1). However, since this was a comparison study, both 1D5 and SP1 were subject to the same limitations imposed by the use of a single TMA core and thus we believe this limitation does not drastically affect our conclusion.
Overall, our data, using both IHC and standardized QIF on fresh FFPE tissue, support previous findings that SP1 is more sensitive than 1D5, and displays a stronger signal-to-background ratio. This would suggest that, in addition to its benefits for cost efficiency, 32 the use of SP1 in a clinical setting may help reduce the false-negative rate. Further studies on response to endocrine therapies in patients with low levels of ER (cases just above the threshold that may be caught with SP1, but not with 1D5) are a critical next step, and these will provide the ultimate insight into whether one antibody is superior in the clinical setting.
